Samsung Biologics
E72266
Samsung Biologics is a South Korean biopharmaceutical company specializing in contract development and manufacturing (CDMO) of biologic drugs for global pharmaceutical and biotech firms.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Samsung Biologics canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T576987 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Samsung Biologics Context triple: [Samsung, subsidiary, Samsung Biologics]
-
A.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
B.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
C.
Samsung C&T
Samsung C&T is a South Korean construction and trading company known for executing major global projects, including landmark skyscrapers and large-scale infrastructure.
-
D.
Roche
Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
-
E.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Samsung Biologics Target entity description: Samsung Biologics is a South Korean biopharmaceutical company specializing in contract development and manufacturing (CDMO) of biologic drugs for global pharmaceutical and biotech firms.
-
A.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
B.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
C.
Samsung C&T
Samsung C&T is a South Korean construction and trading company known for executing major global projects, including landmark skyscrapers and large-scale infrastructure.
-
D.
Roche
Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
-
E.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
contract development and manufacturing organization ⓘ public company ⓘ |
| clientBase |
emerging biotech firms
ⓘ
multinational pharmaceutical companies ⓘ |
| collaboratesWith |
biotech startups
ⓘ
global pharma partners ⓘ |
| country | South Korea ⓘ |
| focusesOn |
biologic therapeutics
ⓘ
biosimilars manufacturing support ⓘ innovative biologics ⓘ |
| foundedBy |
Samsung
ⓘ
surface form:
Samsung Group
|
| hasBusinessArea |
CMC development services
ⓘ
analytical services ⓘ drug product manufacturing ⓘ drug substance manufacturing ⓘ |
| hasCapability |
clinical-scale biologics production
ⓘ
commercial-scale biologics production ⓘ mammalian cell culture ⓘ single-use bioreactor operations ⓘ |
| hasFacilityType | large-scale biomanufacturing plant ⓘ |
| hasKeyBusinessModel |
fee-for-service CDMO model
ⓘ
outsourced biologics manufacturing ⓘ |
| hasOfficialWebsite | https://www.samsungbiologics.com ⓘ |
| headquartersLocation |
Incheon
ⓘ
Songdo International Business District ⓘ |
| industry |
biologics manufacturing
ⓘ
biopharmaceuticals ⓘ contract development and manufacturing ⓘ |
| languageOfName | Korean ⓘ |
| locatedInSpecialEconomicZone | Incheon Free Economic Zone ⓘ |
| offersService |
end-to-end CDMO services
ⓘ
regulatory support ⓘ technology transfer ⓘ |
| parentCompany |
Samsung
ⓘ
surface form:
Samsung Group
|
| partOf | Samsung healthcare business portfolio ⓘ |
| regionServed | global ⓘ |
| serves |
global biotechnology companies
ⓘ
global pharmaceutical companies ⓘ |
| specializesIn |
cell line development
ⓘ
contract development of biologic drugs ⓘ contract manufacturing of biologic drugs ⓘ fill-finish services ⓘ monoclonal antibody production ⓘ process development ⓘ quality control testing ⓘ recombinant protein production ⓘ |
| stockIndex | KOSPI ⓘ |
| tradesOn | Korea Exchange ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Samsung Biologics Description of subject: Samsung Biologics is a South Korean biopharmaceutical company specializing in contract development and manufacturing (CDMO) of biologic drugs for global pharmaceutical and biotech firms.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Samsung